Pro Medicus Ltd (PME) Earnings: Final Dividend per Share A$0.220 with A$161.5M Revenue

Pro Medicus Ltd on Smartkarma

Analyst coverage of Pro Medicus Ltd on Smartkarma by Tina Banerjee highlights the company’s impressive performance in H1FY24. Pro Medicus achieved record sales and profit, fueled by a remarkable 37% year-on-year increase in revenue from North America. This growth trend is expected to continue into H2FY24, with a promising forward revenue potential of A$608 million over the next five years. In the report titled “Pro Medicus Ltd (PME AU): Expanding Footprint in North America Is Making The Image Crystal Clear,” Banerjee emphasizes the significance of the four key contracts secured by PME in H1FY24, with a total contract value of A$200 million and long contract terms ranging from 7 to 10 years.

A look at Pro Medicus Ltd Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Pro Medicus Ltd, a company specializing in software and IT solutions for medical practices, has been given positive Smart Scores across various factors. With high scores in Growth, Resilience, and Momentum, the company is poised for long-term success. The Growth score of 5 indicates strong potential for expanding its services and market presence in the future. Additionally, the high scores in Resilience and Momentum suggest that Pro Medicus has the ability to withstand challenges and maintain a positive trajectory in the market.

Although the Value and Dividend scores are more moderate at 2, the overall outlook for Pro Medicus Ltd remains promising. With a focus on developing software solutions for medical corporations and group practices, the company is well-positioned to capitalize on the increasing digitization of healthcare services. This, combined with its strong scores in Growth, Resilience, and Momentum, indicates a bright future ahead for Pro Medicus Ltd in the evolving healthcare technology landscape.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma